Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Belzutifan + Lenvatinib or Pembrolizumab/Quavonlimab + Lenvatinib vs Pembrolizumab + Lenvatinib in Advanced ccRCC
NCT05899049Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2022
- Primary completion
- Feb 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of belzutifan and pembrolizumab + quavonlimab in clear cell renal cell carcinoma (ccRCC) (3 arms), sponsored by Merck & Co. Primary endpoints: Progression-Free Survival and Overall Survival. Started Jul 2022; status: active, not recruiting.
02
Drugs
belzutifanpembrolizumab + quavonlimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05899049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05899049.